Reports: Mylan eyes $4.5B Meda

|About: Mylan Inc (MYL)|By:, SA News Editor

Pharmaceuticals company Mylan (MYL) is reportedly formulating a largely stock offer to acquire Swedish drug maker Meda (MDABF), which has a market cap of $4.5B, although the U.S. company would probably offer a substantial premium.

A deal could slash Mylan's tax bill if more than 20% of its shares were to be transferred to foreign owners.

The drugs that Mylan would receive include therapies for rheumatoid arthritis, women's health and respiratory disorders.